Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug

Colleen Rivard, Melissa A Geller, Erica Schnettler, manju saluja, Rachel I Vogel, Ashok K Saluja, Sundaram Ramakrishnan

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.

Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.

Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.

Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalGynecologic oncology
Issue number2
StatePublished - Nov 1 2014

Bibliographical note

Publisher Copyright:
© 2014 Elsevier Inc. All rights reserved.


  • Chemotherapy
  • Minnelide
  • Ovarian cancer
  • Triptolide


Dive into the research topics of 'Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug'. Together they form a unique fingerprint.

Cite this